Ignite Creation Date:
2024-10-26 @ 3:37 PM
Last Modification Date:
2024-10-26 @ 3:37 PM
Study NCT ID:
NCT06552598
Status:
RECRUITING
Last Update Posted:
None
First Post:
2024-08-11
Brief Title:
The Safety Tolerability and Efficacy of KD01 in Cervical Malignancies
Sponsor:
None
Organization:
None
Study Overview
Official Title:
The Safety Tolerability and Efficacy of Intratumoral Administration of the Recombinant Oncolytic Adenovirus Injection KD01 in Patients With Cervical Malignancies
Status:
RECRUITING
Status Verified Date:
2024-08
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
No
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
The recombinant oncolytic adenovirus injection KD01 primarily consists of a recombinant human type 5 adenovirus with a deletion in the E3 region where the ADP gene is replaced by the tBID apoptosis protein gene This virus exhibits a conditional replication capability with a 27 base pair deletion in the E1A region corresponding to nucleotides 920-946 of Ad5 This trial is a researcher-initiated clinical study aimed at concurrently evaluating the safety tolerability and preliminary efficacy of intratumoral administration of KD01 in patients with cervical malignancies
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None